Fulgent Genetics annual operating margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fulgent Genetics's operating margin was −28.23% for fiscal 2025.
View full Fulgent Genetics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −28.23% | −2.16 pp |
| 2024 | 2024-12-31 | −26.08% | +41.53 pp |
| 2023 | 2023-12-31 | −67.61% | −96.45 pp |
| 2022 | 2022-12-31 | 28.84% | −39.26 pp |
| 2021 | 2021-12-31 | 68.10% | −0.70 pp |
| 2020 | 2020-12-31 | 68.80% | +70.12 pp |
| 2019 | 2019-12-31 | −1.32% | +22.43 pp |
| 2018 | 2018-12-31 | −23.75% | −5.16 pp |
| 2017 | 2017-12-31 | −18.59% | −23.61 pp |
| 2016 | 2016-12-31 | 5.02% | +57.36 pp |
| 2015 | 2015-12-31 | −52.34% | +25.13 pp |
| 2014 | 2014-12-31 | −77.46% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −42.25% | −18.15 pp |
| Q1 2026 | 2026-03-31 | −48.67% | −21.72 pp |
| Q4 2025 | 2025-12-31 | −43.48% | −22.31 pp |
| Q3 2025 | 2025-09-30 | −18.26% | +5.55 pp |
| Q2 2025 | 2025-06-30 | −24.10% | +2.52 pp |
| Q1 2025 | 2025-03-31 | −26.95% | +6.86 pp |
| Q4 2024 | 2024-12-31 | −21.17% | +193.17 pp |
| Q3 2024 | 2024-09-30 | −23.81% | −24.06 pp |
| Q2 2024 | 2024-06-30 | −26.62% | +2.56 pp |
| Q1 2024 | 2024-03-31 | −33.80% | +3.71 pp |
| Q4 2023 | 2023-12-31 | −214.34% | −160.35 pp |
| Q3 2023 | 2023-09-30 | 0.25% | −0.08 pp |
| Q2 2023 | 2023-06-30 | −29.18% | −39.39 pp |
| Q1 2023 | 2023-03-31 | −37.52% | −100.57 pp |
| Q4 2022 | 2022-12-31 | −53.99% | −113.93 pp |
| Q3 2022 | 2022-09-30 | 0.33% | −69.56 pp |
| Q2 2022 | 2022-06-30 | 10.21% | −54.17 pp |
| Q1 2022 | 2022-03-31 | 63.05% | −11.21 pp |
| Q4 2021 | 2021-12-31 | 59.94% | −16.64 pp |
| Q3 2021 | 2021-09-30 | 69.90% | +7.45 pp |
| Q2 2021 | 2021-06-30 | 64.38% | +49.09 pp |
| Q1 2021 | 2021-03-31 | 74.26% | +98.95 pp |
| Q4 2020 | 2020-12-31 | 76.59% | +81.46 pp |
| Q3 2020 | 2020-09-30 | 62.45% | +47.87 pp |
| Q2 2020 | 2020-06-30 | 15.29% | +11.79 pp |
| Q1 2020 | 2020-03-31 | −24.69% | +9.26 pp |
| Q4 2019 | 2019-12-31 | −4.88% | +13.26 pp |
| Q3 2019 | 2019-09-30 | 14.58% | +29.62 pp |
| Q2 2019 | 2019-06-30 | 3.50% | +22.04 pp |
| Q1 2019 | 2019-03-31 | −33.95% | +13.20 pp |
| Q4 2018 | 2018-12-31 | −18.14% | +30.21 pp |
| Q3 2018 | 2018-09-30 | −15.04% | +17.85 pp |
| Q2 2018 | 2018-06-30 | −18.54% | −15.30 pp |
| Q1 2018 | 2018-03-31 | −47.15% | −51.28 pp |
| Q4 2017 | 2017-12-31 | −48.35% | −69.84 pp |
| Q3 2017 | 2017-09-30 | −32.89% | −19.02 pp |
| Q2 2017 | 2017-06-30 | −3.23% | −27.66 pp |
| Q1 2017 | 2017-03-31 | 4.13% | +22.01 pp |
| Q4 2016 | 2016-12-31 | 21.49% | −19.13 pp |
| Q3 2016 | 2016-09-30 | −13.87% | — |
| Q2 2016 | 2016-06-30 | 24.43% | — |
| Q1 2016 | 2016-03-31 | −17.88% | — |
| Q3 2015 | 2015-09-30 | 40.62% | — |
Over the last five reported fiscal years, Fulgent Genetics's operating margin decreased from 68.80% to −28.23%, a change of −97.04 percentage points. The latest reported quarter, Q2 2026, shows −42.25%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fulgent Genetics filings at SEC.gov ↗